All articles by GlobalData Healthcare

Minimum age threshold introduced for puberty blocker clinical trial

GlobalData's Clinical Trials Database shows the US leads global puberty suppression research with 25% of trials, as the Pathways trial's…
European scientists advocate for integrative approach to obesity prevention

For decades, obesity has posed one of the most formidable threats to public health. Individuals living with obesity are at…
Loneliness interventions do not have strong sustained effects on memory function

Loneliness, defined as a subjective experience of a discrepancy between the preferred interpersonal relationship an individual has and their actual…
Arrowhead gains EU authorisation for Redemplo in evolving FCS market

Arrowhead Pharmaceuticals recently announced that the European Commission (EC) has granted marketing authorisation for Redemplo (plozasiran), an innovative apolipoprotein C…
Addressing sexual minority gaps in cervical and breast cancer screening

According to the US Centers for Disease Control and Prevention (CDC), over 43,000 females and 4,000 females died from breast…

Inequalities in obesity persist in England despite efforts

The increasing prevalence of obesity across the past decades represents one of the most pressing issues in public health, especially…
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s

AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
EAN 2026: NeuroDerm spotlights Onerji fall reduction in advanced Parkinson’s disease

On June 29, at the 12th Congress of the European Academy of Neurology (EAN) 2026, NeuroDerm presented post hoc analysis…
EAN 2026: Meta-analysis finds no added benefit of Radicava/Rilutek combo in ALS

A systematic review and meta-analysis evaluating whether using Daiichi Sankyo’s Radicava (edaravone) and Sanofi’s Rilutek (riluzole) in combination provides additional…
EAN 2026: Regeneron highlights disease control potential of cemdisiran in gMG

Regeneron's Phase III generalised myasthenia gravis (gMG) trial shows high disease control potential of cemdisiran. The Phase III NIMBLE study…